Organization | Government of Kuwait

Government of Kuwait Report issue

Government Phase 1 Phase 3 Phase 4

Organization Overview

First Clinical Trial

2016

NCT04617613

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Kuwait Foundation for the Advancement of Sciences | Ministry of Health, Kuwait

Active Ingredients

Drugs in Phase 4 Trials (5)

amoxicillin (1 trial)

clarithromycin (biaxin) (1 trial)

metronidazole (flagyl) (1 trial)

omeprazole (prilosec) (1 trial)

pioglitazone (actos) (1 trial)

Drugs in Phase 3 Trials (2)

dexmedetomidine (precedex) (1 trial)

ketamine (ketalar) (1 trial)

Drugs in Phase 1 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Other Trials (2)

cyclosporine (sandimmune) (1 trial)

prednisolone (hydeltra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Obesity, Morbid (Phase 3)

Pneumonia (Phase 1)

Pneumonia, Viral (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 10